Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.

about

Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.

Item

http://www.wikidata.org/entity/Q38610162

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Concomitant Therapy with Immun ...... ic Inflammatory Bowel Disease.

@en

type

Item

label

Concomitant Therapy with Immun ...... ic Inflammatory Bowel Disease.

@en

prefLabel

Concomitant Therapy with Immun ...... ic Inflammatory Bowel Disease.

@en

P1476

Concomitant Therapy with Immun ...... ic Inflammatory Bowel Disease.

@en

P2093

Collin Barker

http://www.w3.org/2001/XMLSchema#string

David Israel

http://www.w3.org/2001/XMLSchema#string

Julianna Cheng

http://www.w3.org/2001/XMLSchema#string

Matthew Smyth

http://www.w3.org/2001/XMLSchema#string

Zachary Hamilton

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease

Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease.

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

Significance of low level infliximab in the absence of anti-infliximab antibodies.

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.

Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease.

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.

Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.

P304

1762-1773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MIB.0000000000001212

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kevan Jacobson

P577

2017-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28837517

http://www.w3.org/2001/XMLSchema#string